

SAFETY DATA SHEETS

This SDS packet was issued with item:

078156076

The safety data sheets (SDS) in this packet apply to one or more components included in the items listed below. Items listed below may require one or more SDS. Please refer to invoice for specific item number(s).

071259555 078071823

MATERIAL SAFETY DATA SHEET

Product Name: Naloxone Hydrochloride Injection

1. CHEMICAL PRODUCT AND COMPANY INFORMATION

Manufacturer Name And Address Hospira Inc.
275 North Field Drive
Lake Forest, Illinois USA
60045

Emergency Telephone CHEMTREC: North America: 800-424-9300;
International 1-703-527-3887; Australia (02) 8014 4880

Hospira, Inc., Non-Emergency 224-212-2000

Product Name Naloxone Hydrochloride Injection

Synonyms 17-Allyl-4,5 α epoxy-3,14-dihoxymorphinan-6-one hydrochloride

2. COMPOSITION/INFORMATION ON INGREDIENTS

Active Ingredient Name Naloxone Hydrochloride

Chemical Formula $C_{19}H_{21}NO_4 \cdot HCl$

Preparation Non-hazardous ingredients include Water for Injection. Hazardous ingredients present at less than 1% may include sodium chloride. Hydrochloric acid may be used to adjust the pH. Multiple-dose solutions contain methylparaben and propylparaben which are added as preservatives.

Component	Approximate Percent by Weight	CAS Number	RTECS Number
Naloxone Hydrochloride	0.04	357-08-4	QD2275000

3. HAZARD INFORMATION

Carcinogen List

Substance	IARC	NTP	OSHA
Naloxone Hydrochloride	Not Listed	Not Listed	Not Listed

Emergency Overview Naloxone Hydrochloride Injection is a solution containing naloxone hydrochloride, a competitive antagonist of opioid receptors. Clinically, Naloxone prevents or reverses the effects of opioids including respiratory depression, sedation and hypotension. In the workplace, this material should be considered potentially irritating to the eyes and respiratory tract, and a potent drug. Based on clinical use, possible target organs include the central nervous system and cardiovascular system.

Occupational Exposure Potential Information on the absorption of this product via inhalation or skin contact is not available. Avoid liquid aerosol generation and skin contact.

Signs and Symptoms In the workplace, this material should be considered potentially irritating to eyes. In clinical use, adverse events associated with the use of naloxone hydrochloride injection in postoperative patients include hypotension, hypertension, ventricular tachycardia and fibrillation, dyspnea, pulmonary edema, and cardiac arrest. Death, coma, and encephalopathy have been reported as

Product Name: Naloxone Hydrochloride Injection



sequelae of these events. When given to normal subjects, cognitive impairment and behavioral symptoms, including irritability, anxiety, tension, suspiciousness, sadness, difficulty concentrating, and lack of appetite were reported. In addition, somatic symptoms, including dizziness, heaviness, sweating, nausea, and stomachaches were also noted.

Medical Conditions Aggravated by Exposure	Pre-existing hypersensitivity to this material; pre-existing nervous system or cardiovascular system ailments.
--------------------------------------------------	----------------------------------------------------------------------------------------------------------------

4. FIRST AID MEASURES

Eye contact	Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.
Skin contact	Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.
Inhalation	Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.
Ingestion	Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.

5. FIRE FIGHTING MEASURES

Flammability	None anticipated for this aqueous product.
Fire & Explosion Hazard	None anticipated for this aqueous product.
Extinguishing media	As with any fire, use extinguishing media appropriate for primary cause of fire.
Special Fire Fighting Procedures	No special provisions required beyond normal firefighting equipment such as flame and chemical resistant clothing and self contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Spill Cleanup and Disposal	Isolate area around spill. Put on suitable protective clothing and equipment as specified by site spill procedures. Absorb the liquid with suitable material and clean affected area with soap and water. Dispose of spill materials according to the applicable federal, state, or local regulations.
-----------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

7. HANDLING AND STORAGE

Handling	No special handling required for hazard control under conditions of normal product use.
Storage	No special storage required for hazard control. For product protection, follow storage recommendations noted on the product case label, the primary container label, or the product insert.
Special Precautions	No special precautions required for hazard control.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Exposure Guidelines

Component	Type	Exposure limits			
		mg/m3	ppm	µg/m3	Note
Naloxone Hydrochloride	Not Applicable	N/A	N/A	N/A	None Established

Respiratory protection Respiratory protection is normally not needed during intended product use. However, if the generation of aerosols is likely, and engineering controls are not considered adequate to control potential airborne exposures, the use of an approved air-purifying respirator with a HEPA cartridge (N95 or equivalent) is recommended under conditions where airborne aerosol concentrations are not expected to be excessive. For uncontrolled release events, or if exposure levels are not known, provide respirators that offer a high protection factor such as a powered air purifying respirator or supplied air. A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements must be followed whenever workplace conditions require respirator use. Personnel who wear respirators should be fit tested and approved for respirator use as required.

Skin protection If skin contact with the product formulation is likely, the use of latex or nitrile gloves is recommended.

Eye protection Eye protection is normally not required during intended product use. However, if eye contact is likely to occur, the use of chemical safety goggles (as a minimum) is recommended.

Engineering Controls Engineering controls are normally not needed during the normal use of this product.

9. PHYSICAL/CHEMICAL PROPERTIES

Appearance/Physical State	Liquid
Color	Nonpyrogenic solution in water
Odor	NA
Odor Threshold:	NA
pH:	4.0 (3.0 to 6.5)
Melting point/Freezing point:	NA
Initial Boiling Point/Boiling Point Range:	NA
Evaporation Rate:	NA
Flammability (solid, gas):	NA
Upper/Lower Flammability or Explosive Limits:	NA
Vapor Pressure:	NA
Vapor Density:	NA
Specific Gravity:	NA
Solubility:	soluble in water, in dilute acids, and in strong alkali;
Partition coefficient: n-octanol/water:	NA
Auto-ignition temperature:	NA
Decomposition temperature:	NA

10. STABILITY AND REACTIVITY

Reactivity	Not determined.
Chemical Stability	Stable under standard use and storage conditions.
Hazardous Reactions	Not determined.
Conditions to avoid	Not determined.
Incompatibilities	Not determined.
Hazardous decomposition products	Not determined. During thermal decomposition, it may be possible to generate irritating vapors and/or toxic fumes of carbon oxides (COx), nitrogen oxides (NOx) and hydrogen chloride.
Hazardous Polymerization	Not anticipated to occur with this product.

11. TOXICOLOGICAL INFORMATION

Acute Toxicity

Not determined for the product formulation. Information for the ingredients is as follows:

Ingredient(s)	Percent	Test Type	Route of Administration	Value	Units	Species
Naloxone Hydrochloride	100	LD50	Oral	>1000 >1000	mg/kg mg/kg	Rat Mouse
Naloxone Hydrochloride	100	LD50	Intravenous	107 90	mg/kg mg/kg	Rat Mouse

Aspiration Hazard	None anticipated from normal handling of this product.
Dermal Irritation/Corrosion	None anticipated from normal handling of this product.
Ocular Irritation/Corrosion	None anticipated from normal handling of this product. Inadvertent contact of this product with eyes may produce irritation with redness and tearing.
Dermal or Respiratory Sensitization	None anticipated from normal handling of this product.
Reproductive Effects	Reproduction studies conducted in mice and rats at doses 4-times and 8-times, respectively, the dose of a 50 kg human given 10 mg/day (based on surface area) demonstrated no embryotoxic or teratogenic effects due to naloxone.
Mutagenicity	Naloxone was weakly positive in the Ames mutagenicity and in the in vitro human lymphocyte chromosome aberration test but was negative in the in vitro Chinese hamster V79 cell HGPRT mutagenicity assay and in the in vivo rat bone marrow chromosome aberration study.
Carcinogenicity	Studies in animals to assess the carcinogenic potential of naloxone have not been conducted.
Target Organ Effects	Based on clinical use, possible target organs include the central nervous system and cardiovascular system.

12. ECOLOGICAL INFORMATION

Aquatic Toxicity	Not determined for product.
Persistence/Biodegradability	Not determined for product.
Bioaccumulation	Not determined for product
Mobility in Soil	Not determined for product.

13. DISPOSAL CONSIDERATIONS

Waste Disposal	All waste materials must be properly characterized. Further, disposal should be performed in accordance with the federal, state or local regulatory requirements.
Container Handling and Disposal	Dispose of container and unused contents in accordance with federal, state and local regulations.

14. TRANSPORTATION INFORMATION

DOT STATUS	Not regulated
IMDG STATUS:	Not regulated
ICAO/IATA STATUS:	Not regulated

15. REGULATORY INFORMATION

USA Regulations

Substance	TSCA Status	CERCLA Status	SARA 302 Status	SARA 313 Status	PROP 65 Status
Naloxone Hydrochloride	Not Listed	Not Listed	Not Listed	Not Listed	Not Listed

RCRA Status Not Listed

U.S. OSHA
Classification Target Organ Toxin
Possible Irritant

GHS
Classification *In the EU, classification under GHS/CLP does not apply to certain substances and mixtures, such as medicinal products as defined in Directive 2001/83/EC, which are in the finished state, intended for the final user:

Hazard Class Not Applicable

Hazard Category Not Applicable

Signal Word Not Applicable

Symbol Not Applicable

Prevention P260 - Do not breathe dust/fume/gas/mist/vapors/spray.

Product Name: Naloxone Hydrochloride Injection



Hazard Statement Not Applicable

Response: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists, get medical attention. Wash hands after handling.

Get medical attention if you feel unwell.

EU Classification*

*Medicinal products are exempt from the requirements of the EU Dangerous Preparations Directive. Information provided below is for the pure drug substance Naloxone Hydrochloride

Classification(s): Not Applicable

Symbol: Not Applicable

Indication of Danger: Not Applicable

Risk Phrases: Not Applicable

Safety Phrases:
S23 - Do not breathe vapor.
S24 - Avoid contact with skin.
S25 - Avoid contact with eyes.
S37 - Wear suitable gloves.
S39 - Wear eye / face protection.

16. OTHER INFORMATION:

Notes:

ACGIH TLV	American Conference of Governmental Industrial Hygienists – Threshold Limit Value
CAS	Chemical Abstracts Service Number
CERCLA	US EPA law, Comprehensive Environmental Response, Compensation, and Liability Act
DOT	US Department of Transportation Regulations
EEL	Employee Exposure Limit
IATA	International Air Transport Association
LD50	Dosage producing 50% mortality
NA	Not applicable/Not available
NE	Not established
NIOSH	National Institute for Occupational Safety and Health
OSHA PEL	US Occupational Safety and Health Administration – Permissible Exposure Limit
Prop 65	California Proposition 65
RCRA	US EPA, Resource Conservation and Recovery Act
RTECS	Registry of Toxic Effects of Chemical Substances
SARA	Superfund Amendments and Reauthorization Act
STEL	15-minute Short Term Exposure Limit
TSCA	Toxic Substance Control Act
TWA	8-hour Time Weighted Average

MSDS Coordinator: Hospira GEHS

Date Prepared: 10/27/2011

Obsolete Date: 10/21/2008

Product Name: Naloxone Hydrochloride Injection



Disclaimer:

The information and recommendations contained herein are based upon tests believed to be reliable. However, Hospira does not guarantee their accuracy or completeness NOR SHALL ANY OF THIS INFORMATION CONSTITUTE A WARRANTY, WHETHER EXPRESSED OR IMPLIED, AS TO THE SAFETY OF THE GOODS, THE MERCHANTABILITY OF THE GOODS, OR THE FITNESS OF THE GOODS FOR A PARTICULAR PURPOSE. Adjustment to conform to actual conditions of usage may be required. Hospira assumes no responsibility for results obtained or for incidental or consequential damages, including lost profits, arising from the use of these data. No warranty against infringement of any patent, copyright or trademark is made or implied.



SAFETY DATA SHEET

Revision date: 17-Aug-2016

Version: 1.0

Page 1 of 9

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Naloxone Hydrochloride Injection, USP (Hospira Inc.)

Trade Name: Naloxone Hydrochloride Injection
Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against
Intended Use: Pharmaceutical product

Details of the Supplier of the Safety Data Sheet

Hospira, A Pfizer Company
275 North Field Drive
Lake Forest, Illinois 60045
1-800-879-3477

Hospira UK Limited
Horizon
Honey Lane
Hurley
Maidenhead, SL6 6RJ
United Kingdom

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

Emergency telephone number:
International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification Not classified as hazardous

Label Elements

Signal Word: Not Classified
Hazard Statements: Not classified in accordance with international standards for workplace safety.

Other Hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note: This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

SAFETY DATA SHEET

Material Name: Naloxone Hydrochloride Injection, USP
(Hospira Inc.)
Revision date: 17-Aug-2016

Page 2 of 9

Version: 1.0

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
HYDROCHLORIC ACID	7647-01-0	231-595-7	Skin Corr.1B (H314) STOT SE 3 (H335)	**
Naloxone hydrochloride	357-08-4	206-611-0	Not Listed	0.04

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Water for Injection	7732-18-5	231-791-2	Not Listed	*
Methylparaben	99-76-3	202-785-7	Not Listed	*
Propylparaben	94-13-3	202-307-7	Not Listed	*
SODIUM CHLORIDE	7647-14-5	231-598-3	Not Listed	*

Additional Information:

* Proprietary

** to adjust pH

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact:

Flush eye(s) immediately with plenty of water. If irritation occurs or persists, get medical attention.

Skin Contact:

Wash off immediately with soap and plenty of water. If skin irritation persists, call a physician.

Ingestion:

Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation:

Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure:

For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Medical Conditions

None known

Aggravated by Exposure:

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician:

None

5. FIRE FIGHTING MEASURES

Extinguishing Media:

As for primary cause of fire.

Special Hazards Arising from the Substance or Mixture

PZ03125

SAFETY DATA SHEET

Material Name: Naloxone Hydrochloride Injection, USP
(Hospira Inc.)
Revision date: 17-Aug-2016

Page 3 of 9

Version: 1.0

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards: Not applicable

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

HYDROCHLORIC ACID

ACGIH Ceiling Threshold Limit:	2 ppm
Australia PEAK	5 ppm
	7.5 mg/m ³
Austria OEL - MAKs	5 ppm
	8 mg/m ³
Belgium OEL - TWA	5 ppm
	8 mg/m ³
Bulgaria OEL - TWA	5 ppm
	8.0 mg/m ³
Cyprus OEL - TWA	5 ppm
	8 mg/m ³
Czech Republic OEL - TWA	8 mg/m ³

SAFETY DATA SHEET

Material Name: Naloxone Hydrochloride Injection, USP
(Hospira Inc.)
Revision date: 17-Aug-2016

Page 4 of 9

Version: 1.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Estonia OEL - TWA	5 ppm 8 mg/m ³
Germany - TRGS 900 - TWAs	2 ppm 3 mg/m ³
Germany (DFG) - MAK	2 ppm 3.0 mg/m ³
Greece OEL - TWA	5 ppm 7 mg/m ³
Hungary OEL - TWA	8 mg/m ³
Ireland OEL - TWAs	5 ppm 8 mg/m ³
Italy OEL - TWA	5 ppm 8 mg/m ³
Japan - OELs - Ceilings	2 ppm 3.0 mg/m ³
Latvia OEL - TWA	5 ppm 8 mg/m ³
Lithuania OEL - TWA	5 ppm 8 mg/m ³
Luxembourg OEL - TWA	5 ppm 8 mg/m ³
Malta OEL - TWA	5 ppm 8 mg/m ³
Netherlands OEL - TWA	8 mg/m ³
Poland OEL - TWA	5 mg/m ³
Portugal OEL - TWA	5 ppm 8 mg/m ³
Romania OEL - TWA	5 ppm 8 mg/m ³
Slovakia OEL - TWA	5 ppm 8.0 mg/m ³
Slovenia OEL - TWA	5 ppm 8 mg/m ³
Spain OEL - TWA	5 ppm 7.6 mg/m ³
Switzerland OEL -TWAs	2 ppm 3.0 mg/m ³
Vietnam OEL - TWAs	5 mg/m ³

SODIUM CHLORIDE

Latvia OEL - TWA	5 mg/m ³
Lithuania OEL - TWA	5 mg/m ³

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

Naloxone hydrochloride

Pfizer Occupational Exposure Band (OEB): OEB 3 (control exposure to the range of 10ug/m³ to < 100ug/m³)

Exposure Controls

SAFETY DATA SHEET

Material Name: Naloxone Hydrochloride Injection, USP
(Hospira Inc.)
Revision date: 17-Aug-2016

Page 5 of 9

Version: 1.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Engineering Controls:	Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.
Personal Protective Equipment:	Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).
Hands:	Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)
Eyes:	Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)
Skin:	Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)
Respiratory protection:	Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.)

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Solution	Color:	Colorless
Odor:	No data available.	Odor Threshold:	No data available.
Molecular Formula:	Mixture	Molecular Weight:	Mixture
Solvent Solubility:	No data available		
Water Solubility:	No data available		
pH:	3.0-6.5		
Melting/Freezing Point (°C):	No data available		
Boiling Point (°C):	No data available.		
Partition Coefficient: (Method, pH, Endpoint, Value)			
HYDROCHLORIC ACID			
No data available			
SODIUM CHLORIDE			
No data available			
Methylparaben			
No data available			
Propylparaben			
No data available			
Water for Injection			
No data available			
Naloxone hydrochloride			
No data available			
Decomposition Temperature (°C):	No data available.		
Evaporation Rate (Gram/s):	No data available		
Vapor Pressure (kPa):	No data available		
Vapor Density (g/ml):	No data available		
Relative Density:	No data available		
Viscosity:	No data available		
Flammability:			
Autoignition Temperature (Solid) (°C):	No data available		

PZ03125

SAFETY DATA SHEET

Material Name: Naloxone Hydrochloride Injection, USP
(Hospira Inc.)

Revision date: 17-Aug-2016

Page 6 of 9

Version: 1.0

Flammability (Solids):	No data available
Flash Point (Liquid) (°C):	No data available
Upper Explosive Limits (Liquid) (% by Vol.):	No data available
Lower Explosive Limits (Liquid) (% by Vol.):	No data available

10. STABILITY AND REACTIVITY

Reactivity:	No data available
Chemical Stability:	Stable under normal conditions of use.
Possibility of Hazardous Reactions	
Oxidizing Properties:	None
Conditions to Avoid:	Not determined
Incompatible Materials:	As a precautionary measure, keep away from strong oxidizers
Hazardous Decomposition Products:	Thermal decomposition products may include carbon monoxide, carbon dioxide, oxides of nitrogen and hydrogen chloride.

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information:	The information included in this section describes the potential hazards of the individual ingredients.
Known Clinical Effects:	The most common adverse effects seen during clinical use of this drug include headache, sweating, nausea, decrease in blood pressure (hypotension), increase in blood pressure (hypertension), shortness of breath (dyspnea), increased heart rate (tachycardia), irritability, anxiety, inability to concentrate, lack of appetite.

Acute Toxicity: (Species, Route, End Point, Dose)

HYDROCHLORIC ACID

Rat Oral LD 50 238-277 mg/kg

SODIUM CHLORIDE

Rat Sub-tenon injection (eye) LC50/1hr > 42 g/m³

Rat Oral LD 50 3g/kg

Mouse Oral LD 50 4g/kg

Rabbit Dermal LD 50 > 10g/kg

Naloxone hydrochloride

Rat Oral LD50 > 1000 mg/kg

Mouse Oral LD50 > 1000mg/kg

Rat Intravenous LD50 107mg/kg

Mouse Intravenous LD50 90mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

SODIUM CHLORIDE

Skin Irritation Rabbit Mild

Eye Irritation Rabbit Mild

SAFETY DATA SHEET

Material Name: Naloxone Hydrochloride Injection, USP
(Hospira Inc.)
Revision date: 17-Aug-2016

Page 7 of 9

Version: 1.0

11. TOXICOLOGICAL INFORMATION

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Naloxone hydrochloride

Embryo / Fetal Development	Rat	No route specified	8 times human dose	NOAEL	Not teratogenic
Embryo / Fetal Development	Mouse	No route specified	4 times human dose	NOAEL	Not Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

HYDROCHLORIC ACID

Bacterial Mutagenicity (Ames)	<i>Salmonella</i>	Negative
<i>In Vivo</i> Micronucleus	Rat	Negative

Naloxone hydrochloride

Bacterial Mutagenicity (Ames)	Positive	
<i>In Vitro</i> Chromosome Aberration	Human Lymphocytes	Positive
Mammalian Cell Mutagenicity	HGPRT Hamster	Negative
<i>In Vivo</i> Chromosome Aberration	Rat Bone Marrow	Negative
<i>In Vivo</i> Micronucleus	Negative	

Carcinogen Status:

None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

HYDROCHLORIC ACID

IARC: Group 3 (Not Classifiable)

12. ECOLOGICAL INFORMATION

Environmental Overview:	Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.
Toxicity:	No data available
Persistence and Degradability:	No data available
Bio-accumulative Potential:	No data available
Mobility in Soil:	No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods:	Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.
---------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

SAFETY DATA SHEET

Material Name: Naloxone Hydrochloride Injection, USP
(Hospira Inc.)
Revision date: 17-Aug-2016

Page 8 of 9

Version: 1.0

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Water for Injection

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	231-791-2

Methylparaben

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	202-785-7

HYDROCHLORIC ACID

CERCLA/SARA 313 Emission reporting	1.0 %
CERCLA/SARA Hazardous Substances and their Reportable Quantities:	5000 lb
CERCLA/SARA - Section 302 Extremely Hazardous TPQs	2270 kg
CERCLA/SARA - Section 302 Extremely Hazardous Substances EPCRA RQs	500 lb
California Proposition 65	5000 lb
Inventory - United States TSCA - Sect. 8(b)	Not Listed
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Present
EU EINECS/ELINCS List	Schedule 5
	Schedule 6
	231-595-7

Propylparaben

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed

SAFETY DATA SHEET

Material Name: Naloxone Hydrochloride Injection, USP
(Hospira Inc.)
Revision date: 17-Aug-2016

Page 9 of 9

Version: 1.0

15. REGULATORY INFORMATION

Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	202-307-7

Naloxone hydrochloride

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Australia (AICS):	Present
EU EINECS/ELINCS List	206-611-0

SODIUM CHLORIDE

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	231-598-3

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3

Skin corrosion/irritation-Cat.1B; H314 - Causes severe skin burns and eye damage
Specific target organ toxicity, single exposure; Respiratory tract irritation-Cat.3; H335 - May cause respiratory irritation

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information.

Revision date: 17-Aug-2016

Product Stewardship Hazard Communication

Prepared by: Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet